Charles Stafford, MD
Nephrology · Lexington, KYNPI 1548282601
Payments from drug & device makers
Across 54 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$162
- Gilead$143
- Vifor Pharma, Inc.$107
- Calliditas Therapeutics US Inc.$94
- AstraZeneca$86
- OPKO Pharmaceuticals, LLC$67
- plus $307 from 10 others
What the payments were for
- Food & beverage$966100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 7 | $162 |
| Gilead | 12 | $143 |
| Vifor Pharma, Inc. | 5 | $107 |
| Calliditas Therapeutics US Inc. | 5 | $94 |
| AstraZeneca(2 entities) | 5 | $86 |
| OPKO Pharmaceuticals, LLC | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Amgen | 2 | $48 |
| Bayer | 3 | $44 |
| Aurinia Pharma U.S., Inc. | 2 | $40 |
| Lilly USA, LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| Akebia Therapeutics Inc | 1 | $13 |
How this compares
$966 in reported general payments places this provider in the 45th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metolazone | 244 | $9,147 |
| Metoprolol Succinate | 164 | $2,427 |
| Febuxostat | 19 | $2,298 |
| Allopurinol | 214 | $1,813 |
| Hydralazine Hcl | 145 | $1,564 |
| Hydrochlorothiazide | 176 | $1,162 |
| Amlodipine Besylate | 198 | $1,148 |
| Indapamide | 96 | $1,119 |
| Bumetanide | 57 | $1,091 |
| Spironolactone | 149 | $1,035 |
| Mycophenolate Mofetil | 27 | $969 |
| Carvedilol | 135 | $902 |
| Clonidine | 13 | $730 |
| Clonidine Hcl | 139 | $719 |
| Irbesartan | 29 | $695 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Lexington
- Javier Neyra LozanoLexington$223K
- Sadiq AhmedLexington$140K
- Madhumathi RaoLexington$27K
- Hartmut MallucheLexington$10K
- Amr MohamedLexington$9K
- Thomas FergusonLexington$6K
- Adam DossajiLexington$6K
- Juan Carlos AycinenaLexington$6K
- Khalil RahmanLexington$5K
- Faizan BabarLexington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.